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Notch signaling is a highly conserved intercellular pathway with tightly regulated and
pleiotropic roles in normal tissue development and homeostasis. Dysregulated Notch
signaling has also been implicated in human disease, including multiple forms of cancer,
and represents an emerging therapeutic target. Successful development of such
therapeutics requires a detailed understanding of potential on-target toxicities. Here, we
identify autosomal dominant mutations of the canonical Notch ligand Jagged1 (or JAG1) as
a cause of peripheral nerve disease in 2 unrelated families with the hereditary axonal
neuropathy Charcot-Marie-Tooth disease type 2 (CMT2). Affected individuals in both
families exhibited severe vocal fold paresis, a rare feature of peripheral nerve disease that
can be life-threatening. Our studies of mutant protein posttranslational modification and
localization indicated that the mutations (p.Ser577Arg, p.Ser650Pro) impair protein
glycosylation and reduce JAG1 cell surface expression. Mice harboring heterozygous
CMT2-associated mutations exhibited mild peripheral neuropathy, and homozygous
expression resulted in embryonic lethality by midgestation. Together, our findings highlight
a critical role for JAG1 in maintaining peripheral nerve integrity, particularly in the recurrent
laryngeal nerve, and provide a basis for the evaluation of peripheral neuropathy as part of
the clinical development of Notch pathway–modulating therapeutics.
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Introduction
The Notch pathway is a highly conserved cell-cell signaling 
mechanism that functions in virtually all tissues to regulate 
multiple aspects of cell fate and homeostasis. Dysregulation of 
Notch signaling outputs has been shown to cause or contribute 
to several human diseases, including developmental syndromes 
and adult-onset diseases. Due to its role as an oncogenic driver 
in several forms of cancer, the Notch pathway is an emerging 
therapeutic target (1). The on-target toxicity and side effects 
resulting from pan-Notch inhibition (1) have prompted the 
development of approaches targeting specific Notch pathway 
components (1, 2). Given the highly pleotropic roles of Notch sig-
naling, however, continued identification of Notch-dependent 
tissues will play an important role in the development of such 
targeted approaches for clinical use.
Here, we show that autosomal dominant mutations in the 
canonical Notch ligand Jagged1 (or JAG1) are a cause of the 
peripheral nerve disease Charcot-Marie-Tooth disease type 2 
(CMT2). Individuals harboring these mutations exhibit severe 
vocal fold paresis, a rare clinical feature of peripheral neuropathy 
(3) that can be life life-threatening. These findings identify a key 
role for JAG1 in maintaining peripheral nerve integrity and high-
light potential on-target toxicities that may be associated with 
JAG1-targeted therapeutics.
Results and Discussion
We examined 2 unrelated CMT2 families with similar clinical 
features (Figure 1 and Supplemental Tables 1 and 2; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI128152DS1). Vocal fold paresis was severe, 
often requiring tracheostomy (Figure 1E and Supplemental 
Table 1), whereas neuropathy of the limbs was mild (Supplemen-
tal Tables 1 and 2). Whole exome sequencing (WES) of 3 affected 
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ual II.8, a sibling of II.7. Importantly, however, individual II.8 
did not harbor the c.1731C>G substitution, indicating that this 
variant likely arose de novo in II.7. WES of individual III.2 from 
family 2 also did not identify variants in known neuropathy- 
associated genes (Figure 1D and Supplemental Tables 1 and 2), 
but did reveal a second variant in JAG1, c.1948T>C (exon 15), 
which cosegregated with the phenotype in all 5 affected fam-
ily members from whom DNA was available (Figure 1D). Nei-
ther the c.1731C>G variant (family 1) nor the c.1948T>C vari-
ant (family 2) is present in the Genome Aggregation Database 
individuals from family 1 (Figure 1A, individuals II.7, III.5, and 
III.7) did not identify variants in genes known to cause CMT. 
Of 15 candidate variants, only 1 segregated appropriately after 
Sanger sequencing of 14 additional affected and unaffected 
family members: a variant c.1731C>G in exon 14 of the JAG1 
gene (Figure 1, A and B). We performed haplotype analysis to 
investigate the possibility that this mutation arose de novo in 
individual II.7, given his lack of affected parents and siblings. 
The disease-associated haplotype shared among all 4 affected 
individuals of family 1 (Figure 1C) was also shared by individ-
Figure 1. JAG1 mutations segregate with CMT2 and vocal fold paresis in 2 unrelated families. (A) Pedigree of family 1 demonstrating affected subjects in 
3 generations (arrow indicates proband). The genotypes of individuals whose DNA was Sanger sequenced are shown. The parents of II.7 are deceased, but 
did not show any signs of peripheral neuropathy or vocal fold paresis. (B) Sanger sequencing of the JAG1 gene from unaffected (II.6 and II.8) and affected 
(II.7, III.5, III.7, IV.2) individuals from family 1, showing the heterozygous c.1731C>G variant (asterisks). (C) Haplotype analysis of family 1, with the CMT2- 
associated haplotype shown in green. (D) Pedigree of family 2 demonstrating affected subjects across 4 generations. Family members whose DNA was 
examined have been numbered. (E) Photographs of individual IV.2 (family 1) illustrating her tracheostomy, scoliosis repaired with surgeries, and mild pes 
cavus (clockwise from top left).
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there was no report of vertebral malformations. Detailed clin-
ical case histories are provided in the supplemental material.
The 2 CMT2-associated JAG1 variants both resulted in 
missense substitutions of serine residues (p.Ser577Arg, family 
1; p.Ser650Pro, family 2) within highly conserved regions of 
the JAG1 extracellular domain (Figure 2, A and B). Both sub-
stitutions are predicted to be deleterious by in silico analyses 
(gnomAD). Dominant mutations in JAG1 have previously been 
shown to cause Alagille syndrome, which is characterized by 
defects in bile ducts, heart, kidney, facies, and vertebrae (4, 
5). There was no history of cardiac, kidney, or liver disease in 
affected individuals in either CMT2 family nor evidence of 
jaundice, xanthomas, or facial dysmorphology. Family 1 indi-
vidual IV.2 required spine surgery for scoliosis (Figure 1E), but 
Figure 2. Neuropathy-associated mutations affect conserved amino acids in the extracellular domain of JAG1. (A) Clustal Omega alignments of the JAG1 
protein from divergent species. The p.Ser577Arg and p.Ser650Pro mutations both disrupt serine residues located in highly conserved regions of JAG1. (B) 
The domain structure of JAG1, with the CMT2-associated mutations indicated in red. Though Alagille syndrome is primarily caused by JAG1 gene deletion or 
truncating mutations, a number of missense mutations (shown in black) have been described (see Supplemental Methods for references). Of the 42 amino 
acids mutated in Alagille syndrome, 20 are cysteine residues and none are serine residues; few occur in proximity to Ser577 and Ser650. (C) A schematic of 
3 canonical EGF-like repeats is shown, along with 2 proposed models for JAG1 EGF-like repeats 9–11. In model 1, residues 562–585 are split between EGF-
like repeats 9 and 10, including a potential disulfide bridge between residues 567 and 572 preceding the start of repeat 10. Model 1 requires 2 insertions, 1 
before and 1 within repeat 10. In model 2, residues 562 to 585 are included as a single insertion in the second loop of EGF-like repeat 10. (D) 3D modeling 
shows that Ser577 and Ser650 may reside on the same surface of the JAG1 extracellular domain (model 2).
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cysteine residues thought to contribute to disulfide bridges (Fig-
ure 2B). Since there is no experimentally determined structure 
of the region of JAG1 in which Ser577 and Ser650 reside (6), we 
performed structural modeling to predict how this region might 
interact with the surrounding EGF-like repeats and generated 
2 possible models (Figure 2C). While model 1 follows current 
database annotations (Supplemental Figure 1), model 2 is simi-
larly plausible. Interestingly, in model 2, Ser577 and Ser650 are 
located on the same surface of the protein (Figure 2D), raising 
the possibility that their mutation could disrupt a ligand interac-
tion with this portion of the extracellular domain or comparably 
alter the mechanical forces required to activate Notch receptors 
during JAG1-Notch interactions (7).
(Supplemental Table 3). Whereas Ser650 is situated within a 
known domain (EGF-like repeat 11), Ser577 is located within a 
region (residues 562–585) that has traditionally been annotated 
as residing between EGF-like repeats 9 and 10 (ref. 4 and Fig-
ure 2B). Notably, this region also contains 3 cysteine residues, 
raising the possibility that it represents a shorter noncanonical 
EGF-like repeat and thereby contributes to disulfide bridges 
affecting the structure of the extracellular domain. Although 
the majority of Alagille syndrome–causing JAG1 mutations are 
truncating or nonsense mutations, a minority are missense 
mutations. These missense mutations occur primarily in JAG1 
domains that interact directly with Notch receptors (C2 and DSL 
domains, EGF-like repeats 1–3; ref. 6), the signal peptide, or at 
Figure 3. Neuropathy-associated muta-
tions alter JAG1 cell surface expression and 
glycosylation. (A) Representative images 
of WT and mutant JAG1-FLAG immunolo-
calization in transfected COS-7 cells. Scale 
bars: 10 μm. (B–E) Representative Western 
blots of whole cell lysates from HEK293T 
(B) and MN-1 (D) cells transfected with WT 
or mutant JAG1-FLAG. Arrowheads indicate 
the complex (upper band) and simple (lower 
band) glycosylated forms of JAG1. (C and E) 
Densitometry-based quantification of the 
proportion of total JAG1 represented by the 
higher molecular weight band (C, HEK293T, 
n = 6 per condition; E, MN-1, n = 5 per con-
dition). **P < 0.01; ***P < 0.001, Dunnett’s 
test. EV, empty vector. (F–G) Representa-
tive Western blot (F) and quantification (G) 
of JAG1 cell surface biotinylation assays.  
n = 7 for WT and p.Ser577Arg; n = 4 for 
p.Ser650Pro. ***P < 0.001, 1-sample t 
test. (H–I) Western blot analysis (H) and 
quantification (I) of the ADAM17-cleaved 
C-terminal fragment (CTF) of JAG1, a reflec-
tion of the amount of full-length (FL) JAG1 
trafficked to the cell surface (11). n = 7 for 
WT; n = 9 for p.Ser577Arg; n = 6 for p.Ser-
650Pro. ***P < 0.001 by Dunnett’s test.
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at the plasma membrane (Figure 3A and Supplemental Figure 2). 
JAG1Ser577Arg and JAG1Ser650Pro were also present at the plasma mem-
brane, but both mutants also exhibited significant immunolocal-
ization with the ER marker Sec61b, suggesting partial retention in 
the ER and reduced cell surface expression relative to WT (Figure 
3A and Supplemental Figure 2). In contrast, the well-characterized 
To investigate the consequences of the p.Ser577Arg and 
p.Ser650Pro mutations on JAG1, we performed a series of in vitro 
studies (Figure 3). Immunocytochemical analysis of transiently 
transfected COS-7 cells exposed to an anti-JAG1 extracellular 
domain antibody prior to permeabilization and staining for total 
JAG1 demonstrated expression of WT JAG1 (JAG1WT) primarily 
Figure 4. Homozygous expression of the JAG1S577R mutation causes embryonic lethality in mice, while heterozygous expression results in mild peripher-
al neuropathy. (A and B) Genotyping of postnatal (A) and embryonic (B; E8.5–E12.5) mice generated from heterozygous intercrosses demonstrates embry-
onic lethality in Jag1S577R/S577R mice. (C–F) Jag1S577R/+ mice display impaired performance in the inverted grid test (C) as well as reductions in CMAP area (D 
and E), but not latency (F). Representative CMAP traces are shown in D. n = 11 for WT; n = 19 for Jag1S577R/+. *P < 0.05; **P < 0.01, 2-tailed Student’s t test. 
(G and H) TEM reconstructions of the recurrent laryngeal nerve of WT (G) and Jag1S577R/+ (H) mice. Insets show higher magnification images of individual 
myelinated axons. Scale bars: 10 μm; 2 μm (insets). Arrowheads indicate regions of focally folded myelin (15). (I–K) Myelinated axons in the recurrent laryn-
geal nerve of Jag1S577R/+ mice exhibit normal g-ratios (I) and numbers of actively degenerating axons (J), but an increased incidence of focally folded myelin 
(K) For I, n = 350 axons from 3 WT mice; n = 410 axons from 3 Jag1S577R/+ mice. For J and K, n = 3 for WT and Jag1S577R/+. *P < 0.05, 2-tailed Student’s t test. 
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were observed at E8.5 (but not at later time points), confirming a 
clear functional relevance of the p.Ser577Arg substitution and sug-
gesting that embryonic lethality primarily occurs immediately pri-
or to E8.5. Motor behavioral assessments of Jag1S577R/+ mice (16–20 
months of age) revealed impaired performance in the inverted grid 
test of limb strength relative to WT littermates (Figure 4C), but 
normal performance in the accelerating rotarod assay (Supplemen-
tal Figure 4D). Jag1S577R/+ mice (19–23 months of age) also exhibited 
reductions in compound muscle action potential (CMAP) area in 
assessments of peripheral nerve electrophysiology (Figure 4, D and 
E), with a slight, but nonsignificant (P = 0.054; by 2-tailed Student’s 
t test), reduction in CMAP distal latency (Figure 4F). Morphologi-
cal assessments of the recurrent laryngeal nerve in Jag1S577R/+ mice 
at 19 to 23 months of age (Figure 4, G–K) did not reveal alterations 
of axon or myelin sheath diameter (g-ratio; Figure 4I), numbers 
of actively degenerating axons (Figure 4J), total myelinated axon 
number (Supplemental Figure 4E), or neuromuscular junction 
innervation (Supplemental Figure 4, F and G) at this time point, but 
did demonstrate an increased frequency of focally folded myelin 
(ref. 15 and Figure 4K). This peripheral nerve abnormality has been 
observed with aging (16), several forms of hereditary neuropathy 
(15), and experimental disruptions of axon-glial interactions (17, 
18). Together, these findings indicate that heterozygous expression 
of the p.Ser577Arg mutation causes a mild peripheral neuropathy 
in mice. The severe and mild phenotypes observed with homozy-
gous and heterozygous expression of the mutant Jag1 allele, respec-
tively, are similar to gene dosage effects observed in mouse models 
of other autosomal dominant forms of axonal neuropathy (19–22).
Together, our clinical, genetic, biochemical, and mouse model 
findings implicate JAG1 mutations as a cause of CMT2 with severe 
vocal fold paresis. These results broaden the spectrum of diseases 
associated with alterations in the Notch pathway and point to a 
key role for JAG1 in peripheral nerve, particularly the recurrent 
laryngeal nerve. The absence of Alagille syndrome phenotypes 
in both CMT2 families suggests that contrasting disease mecha-
nisms underlie the 2 disorders. The vast majority of Alagille syn-
drome–causing mutations are JAG1 gene deletions or truncating 
mutations, suggesting that haploinsufficiency represents the 
primary disease mechanism (4, 5). The identification of Alagille 
syndrome–causing mutations in NOTCH2 further points to a key 
role of reduced JAG1/NOTCH2 signaling in disease pathogenesis 
(4, 5). The specific involvement of peripheral nerve in CMT2 sug-
gests that p.Ser577Arg and p.Ser650Pro may precipitate disease 
through a more complex, or tissue-specific, mechanism or mech-
anisms, potentially involving specific reductions or alterations in 
Notch receptor trans-activation and/or cis-inhibition. Within the 
peripheral nervous system, JAG1 is expressed by both axons and 
Schwann cells, whereas Notch receptor expression appears to 
occur principally in Schwann cells (23, 24). Elevated expression of 
JAG1 has also been described in reactive spinal cord astrocytes in 
a mouse model of the inherited neurodegenerative disease spinal 
muscular atrophy (25). While Notch signaling has been shown to 
control several important aspects of peripheral nerve develop-
ment and plasticity (23), the specific roles played by JAG1 in the 
peripheral nervous system remain to be determined. Continued 
elucidation of these roles will be central to identifying potential 
pathological and pathophysiological alterations in peripheral 
Alagille syndrome–causing mutant JAG1Arg184His localized solely to 
the ER (Figure 3A, Supplemental Figure 2, and refs. 8, 9).
The extracellular domains of Notch receptors and ligands, 
including JAG1, are extensively posttranslationally modified by 
glycosylation within the ER (simple glycosylation) and Golgi appa-
ratus (complex glycosylation) (10). As previous studies have shown 
that only JAG1 protein that has undergone complex glycosylation 
is trafficked to the cell surface (9), we assessed the glycosyla-
tion profiles of the 2 CMT2-associated mutants by Western blot 
analysis. In whole cell lysates from HEK293T and MN-1 (a motor 
neuron-like cell line) cells, JAG1WT migrated as a doublet in the 140 
to 170 kDa range, with approximately equivalent expression of the 
2 bands (Figure 3, B–E, and ref. 9). The higher and lower molecular 
weight bands represent complex and simple glycosylated forms of 
JAG1, respectively, based on differential sensitivity to deglycosyla-
tion treatments (refs. 8 and 9 and Supplemental Figure 3, A and B). 
While JAG1Ser577Arg and JAG1Ser650Pro also migrated as doublets, the 
complex glycosylated form represented a significantly reduced 
portion of the total protein for both mutants (Figure 3, B–E). Con-
sistent with the reduction in complex glycosylation, cell surface 
biotinylation experiments in HEK293T cells demonstrated signifi-
cantly reduced, but not absent, plasma membrane expression of 
the 2 mutants (Figure 3, F and G). Assessments of JAG1 cleavage 
at the plasma membrane by ADAM17 further support reduced 
cell surface expression of the mutant proteins (ref. 11 and Figure 
3, H and I). In contrast, the Alagille syndrome–causing JAG1Arg184His 
mutant migrates as a single band representing the simple glyco-
sylated form (Figure 3, B–E, and Supplemental Figure 3, A and B) 
and is not detectable in the cell surface fraction (Figure 3, F and G). 
Together, these data demonstrate that both neuropathy-associated 
mutant forms of JAG1 are expressed at the cell surface, but at sig-
nificantly lower levels than WT protein.
Given that Notch signaling outcomes are highly context and 
cell type dependent (12, 13), we adopted an in vivo approach to 
explore the cellular consequences of the CMT2-associated muta-
tions, using CRISPR/Cas9 gene editing to knock the p.Ser577Arg 
mutation into the mouse Jag1 gene (C57BL/6J background; Sup-
plemental Figure 4, A and B). The JAG1 proteins of humans and 
mice exhibit high homology (96.6% shared sequence identity), 
including the S577 residue (Figure 2A and Supplemental Figure 5). 
Past attempts to generate mouse models of Alagille syndrome have 
demonstrated few relevant phenotypes in mice heterozygous for a 
JAG1 null allele (Jag1tm1Grid/+) and lethality by E10.5 in homozygous 
mice (5). Mice homozygous for a loss-of-function allele (Jag1Ndr/Ndr) 
on a C3H/C57BL6 background exhibit partial embryonic lethality, 
with surviving mice exhibiting liver, heart, and kidney defects and 
craniofacial dysmorphology, consistent with Alagille syndrome 
(14). As these findings suggest species-specific differences in sen-
sitivity to alterations in JAG1 gene dosage, we established hetero-
zygous intercrosses of the Jag1S577R mouse line to generate both 
heterozygous (Jag1S577R/+) and homozygous (Jag1S577R/S577R) progeny. 
Genotyping of more than 100 pups generated from these crosses 
identified no Jag1S577R/S577R mice, whereas WT and Jag1S577R/+ pups 
were born at a Mendelian ratio of approximately 1 to 2 (Figure 4A 
and Supplemental Table 4). Examination of over 70 embryos at ges-
tational ages E8.5 to E12.5 revealed only a single living Jag1S577R/S577R 
embryo (Figure 4B). In addition, several dead Jag1S577R/S577R embryos 
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ology was performed by KLM and MHF. The order of the 2 co–first 
authors was determined based on the scope of their respective 
contributions.
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